ArticleCell death discovery2022

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.

Narissa Parry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.